| 1 | Insulin-AKT1-YBX1 Regulation of ANGPTL8 Promote Lipogenesis in |
|------|---|
| 2 | Obstructive Sleep Apnea-Associated Dyslipidemia |
| 3 | Yuenan Liu ^{a,f} , Haolin Yuan ^{a,f} , Anzhao Wang ^{a,f} , Shengming Wang ^a , Xu Xu ^a , Junhui Hu ^a , |
| 4 | Jinhong Shen ^a , Yiming Hu ^a , Xinyi Li ^a , Niannian Li ^a , Zhenfei Gao ^a , Xiaoxu Zhang ^a , |
| 5 | Xiaoman Zhang ^a , Yupu Liu, Huajun Xu ^a , Hongliang Yi ^a , Jian Guan ^{a,*,} , Zhiqiang Li ^{d,e,*} , |
| 6 | Yongxu Zhao ^{b,c,*} , Shankai Yin ^{a,*} , Feng Liu ^{a,*} |
| 7 | Affiliations |
| 8 | ^a Department of Otolaryngology Head and Neck Surgery, Shanghai Key Laboratory of |
| 9 | Sleep Disordered Breathing, Otolaryngological Institute of Shanghai Jiao Tong |
| 10 | University, Shanghai Jiao Tong University School of Medicine Affiliated Sixth |
| 11 | People's Hospital, Shanghai 200233, China. |
| 12 | ^b Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai |
| 13 | 201203, China. |
| 14 | ^c Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research |
| 15 | Institute for Drug Discovery, Shandong 264117, China. |
| 16 | ^d The Affiliated Hospital of Qingdao University & The Biomedical Sciences Institute |
| 17 | of Qingdao University (Qingdao Branch of SJTU Bio-X Institutes), Qingdao |
| 18 | University, Qingdao, 266003, China. |
| 19 | ^e Bio-X Institutes, Key Laboratory for the Genetics of Developmental and |
| 20 | Neuropsychiatric Disorders (Ministry of Education), the Collaborative Innovation |
| 21 | Center for Brain Science, Shanghai Jiao Tong University, Shanghai, 200030, China. |
| 22 | ^f These authors contributed equally to this work. |
| 23 | * Corresponding authors. |
| 24 | E-mail addresses: guanjian0606@sina.com (J Guan), lizqsjtu@163.com (Z Li), |
| 25 | zhaoyongxu@simm.ac.cn (Y Zhao), skyin@sjtu.edu.cn (S Yin), liufeng@sibs.ac.cn (F |
| 26 N | DTE: m)s preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. |

27 Leading contact: <u>liufeng@sibs.ac.cn</u> (F Liu)

28

29 Abstract

Dyslipidemia is a hallmark of obstructive sleep apnea (OSA)-induced metabolic 30 syndrome, yet the mechanisms remain poorly understood. We conducted a 31 genome-wide association study on lipid traits in the OSA cohorts, identifying the 32 33 SNP rs3745683 in ANGPTL8, significantly associated with reductions in multiple lipid traits. ANGPTL8, an essential lipogenic hormone and potential therapeutic 34 target for metabolic syndrome, showed elevated expression in OSA patients 35 compared to healthy controls, strongly correlated with increased insulin levels. 36 Notably, ANGPTL8 expression can be upregulated by insulin stimulation, 37 indicating it as an insulin-responsive hormone regulating dyslipidemia in OSA. 38 Mechanistically, SNP rs3745683 attenuated ANGPTL8 transcription by 39 inhibiting its binding to transcription factor YBX1. Insulin prompted AKT1 to 40 41 phosphorylate YBX1 at Ser102, facilitating YBX1's nuclear translocation and subsequent regulation of ANGPTL8 expression and lipid synthesis. Specific 42 knockdown of YBX1 in mouse liver confirmed its necessity for ANGPTL8 43 expression and hepatic lipid synthesis in vivo. Our findings highlight ANGPTL8 44 as a critical regulator of dyslipidemia in OSA patients, offering a promising 45 therapeutic avenue for managing metabolic syndrome in OSA. 46

47

Keywords ANGPTL8, dyslipidemia, GWAS, obstructive sleep apnea, YBX1

- 48
- 49
- 50

51



ANGPTL8 serves as a crucial regulator of lipid metabolism abnormalities in 57 obstructive sleep apnea. OSA elevates insulin levels, which, through the AKT1-YBX1 signaling pathway, interact with genetic variants in OSA patients to influence the 58

59 expression of ANGPTL8 and lipid synthesis.

| 60 | • | The genetic variant rs3745683 in ANGPTL8 is associated with lipid profiles in |
|----|---|---|
| 61 | | patients with obstructive sleep apnea (OSA). |

- Elevated insulin levels observed in OSA patients enhance the expression of
 ANGPTL8 and lipid synthesis.
- Insulin signaling facilitates the phosphorylation and nuclear translocation of
 YBX1, which interacts with rs3745683, collectively influencing the expression of
 ANGPTL8 and lipid biosynthesis.
- 67 The paper explained

68 Problem

Obstructive sleep apnea (OSA) increases the risk of dyslipidemia, which can lead to
 serious cardiovascular complications. However, the underlying mechanisms remain
 unclear.

72 **Results**

The GWAS identified a single nucleotide polymorphism (SNP), rs3745683, in 73 ANGPTL8, which is significantly associated with decreases in multiple lipid traits in 74 the OSA cohort. Deficiency of ANGPTL8 led to impaired lipogenesis in hepatocytes 75 76 and adjpocytes. Rs3745683 attenuated ANGPTL8 transcription by suppressing the binding of its proximal element to the upstream transcription factor YBX1. OSA 77 patients exhibited elevated insulin levels, which were highly correlated with increased 78 ANGPTL8 expression. In response to insulin, AKT1 interacted with YBX1 and 79 phosphorylated it at Ser102, promoting its nuclear translocation and subsequent 80 regulation of ANGPTL8 expression and lipid synthesis. Specific knockdown of YBX1 81 in mouse liver confirmed that YBX1 is required for ANGPTL8 expression and hepatic 82 lipid synthesis in vivo. 83

84 Impact

Our findings highlight ANGPTL8 as a critical regulator of dyslipidemia in OSA patients. We demonstrated that the insulin-AKT1-YBX1 signaling pathway, in conjunction with genetic variations, modulates ANGPTL8 expression and lipid metabolism in OSA-associated dyslipidemia and offered a promising therapeutic avenue for managing metabolic syndrome in OSA patients.

- 90
- 91

92 Introduction

Metabolic syndrome (MS) is distinguished by the co-occurrence of numerous 93 metabolic abnormalities, including central obesity, hyperglycemia (comprising 94 95 impaired glucose tolerance and diabetes), hyperinsulinemia, hypertension, and dyslipidemia. It constitutes a significant predisposition to cardiovascular disease 96 (CVD) [1]. Substantial research consistently underscores that individuals afflicted 97 98 with obstructive sleep apnea (OSA), a prevalent sleep-disordered breathing disorder 99 characterized by chronic and intermittent hypoxia as well as enduring sleep 100 deprivation, exhibit a notably heightened susceptibility to developing MS when juxtaposed with the general populace [2-4]. Furthermore, there is compelling evidence 101 that OSA considerably augments the risk of manifesting a spectrum of comorbidities 102 103 associated with metabolic syndrome, while concurrently contributing to escalated 104 all-cause mortality [3, 5]. Nonetheless, the exact molecular underpinnings governing 105 these relationships remain elusive and necessitate further scholarly inquiry.

Alterations in endocrine hormones represent pivotal factors in the genesis of metabolic syndrome. Angiopoietin like 8 (ANGPTL8), a hepatic and adipose tissue-secreted protein hormone with evolutionary conservation across multiple species, plays an indispensable role in metabolic regulation [6]. A growing body of research, founded on clinical data and murine models, substantiates the central role of ANGPTL8 as a responsive agent in the domains of food intake, estrogen, and insulin signaling within the intricate terrain of glycemic and lipid metabolism [7, 8]. This

multifaceted protein exhibits close associations with a spectrum of human conditions, 113 including dyslipidemia [9], obesity [10], metabolic syndrome [10, 11], cardiovascular 114 maladies [12], type 2 diabetes mellitus (T2DM) [13], and obstructive sleep apnea [14, 115 15]. In its current sphere of investigation, ANGPTL8, operating as an endocrine 116 hormone, orchestrates a symphony of effects by modulating the physiological 117 functions of diverse organs and tissues throughout the body, including the liver [16, 118 17], pancreas [18], muscles [19], and adipose tissue [19, 20]. Collectively, these 119 120 studies contribute to the intricate tapestry of metabolic processes that oversee glycemic and lipid regulation. 121

In the human context, the regulation of metabolism and the etiology of metabolic 122 diseases frequently bear a discernible genetic signature [21-24]. Comprehensive 123 human genetic inquiries, encompassing whole-genome association analyses, 124 irrefutably substantiate the intimate interconnection between ANGPTL8 and a gamut 125 of metabolic disorders [25-28]. Moreover, these investigations unveil a multitude of 126 127 genetic loci within ANGPTL8 intricately intertwined with aberrations in lipid 128 metabolism [25-28]. Among these loci, rs2278426 (C>T), a non-synonymous single nucleotide polymorphism (SNP) within ANGPTL8, correlates with decreased serum 129 levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein 130 cholesterol (HDL-C) in African Americans and Hispanics [29]. Another SNP, 131 132 rs3745683 (G>A), situated in the ANGPTL8 promoter region, has been associated with serum HDL-C levels [26]. However, past investigations have provided limited 133 insights into how genetic variations in ANGPTL8 interact with physiological or 134 pathological factors, thereby elucidating the specific mechanisms by which it 135 136 modulates the biological functions governing glucose and lipid metabolism.

In our antecedent study, leveraging the Shanghai Sleep Health Study (SSHS) cohort, comprising 5,438 PSG-confirmed OSA patients and 15,152 non-OSA healthy controls, we conducted an extensive genome-wide association study (GWAS). Within this ambit, we identified 18 significant loci linked to susceptibility to OSA and OSA-related quantitative traits, encompassing parameters such as sleep architecture, 142 respiratory events, and oxygen saturation [30]. Concurrently, within the purview of this research undertaking, we conducted a GWAS analysis on the metabolic profiles 143 of the same cohort. This analysis unveiled a notable correlation between a SNP 144 rs3745683(G>A) in the ANGPTL8 promoter region and a diverse array of metabolic 145 traits, including but not limited to HDL-C, TC, and ApoA. In delving further into the 146 transcriptional regulatory mechanisms governing rs3745683(G>A), we unveiled the 147 intricate molecular apparatus modulating ANGPTL8 expression. Specifically, our 148 149 investigations illuminated the role of the insulin-AKT1 signaling pathway in modulating ANGPTL8 expression through the orchestration of nuclear translocation 150 of the transcription factor YBX1. We unveiled a potential regulatory pathway 151 underlying the dysregulation of lipid metabolism caused by OSA. 152

153 Materials and Methods

154 Clinical cohort

Individuals enrolled in this study were from SSHS cohort. The SSHS study adheres to
the Declaration of Helsinki and is registered in the Chinese Clinical Trial Registry
(ChiCTR1900025714). It has received ethical approval from the Ethics Committee of
Shanghai Sixth People's Hospital (Approval No.2021-KY-76), and the collection and
preservation of genetic samples have been authorized by the China Human Genetic
Resources Management Office (Approval No. 2022-BC0010).

The cohort consists of 5,438 OSA cases and 15,152 controls from Han Chinese. The individuals, genotyping and statistical analysis strategies were described in detail in our previous study [30]. Next, subjects from SSHS in this study, were screened according to the following exclusion criteria. (i) age less than 18 years old; (ii) history of OSA treatment; (iii) history of metabolic disorders treatment (i.e., hyperlipemia, T2MD); (iv) cardiovascular disease; (v) unavailable standard polysomnography data. A total 4,692 participants were ultimately analyzed in this study.

168 Animal studies

169 All animal studies were supervised and approved by the Animal Care Committee of

Shanghai Six People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine, and the animal welfare ethics acceptance number is No:2019-0237. Four-week-old C57BL/6N SPF male mice were purchased from GemPharmatech (China), The mice were randomly allocated to the experimental group or control group, and kept at humidity environment with free access to food and water in a standard light-dark cycle.

176 Before the adeno-associated virus (AAV) construction, the target sequence used against mouse Ybx1 was screened from three candidates in the primary hepatocyte. 177 AAV2/8 carrying mouse Ybx1-shRNA (AAV2/8-TBG-Ybx1-shRNA) and the control 178 vectors (AAV2/8-TBG-EV) were constructed, amplified, and purified by Obio 179 Technology (China). The target sequence used against mouse Ybx1 was as follows: 180 181 5'-CCACGCAATTACCAGCAAA-3'. AAV diluted in saline and injected via the tail vein of mice $(2 \times 10^{11} \text{ vg per mouse})$. Three weeks later, immunoblotting or RT-qPCR 182 were performed to examine the expression levels of *Ybx1* and *Angptl8* in mice livers. 183 184 Then, the rest mice were fed with high fat-diet (HFD, 60% fat caloric content, 185 Research Diets, D12492) and the body weights and food intakes were measured weekly. For 12 weeks of HFD feeding, we performed GTT on these mice. For 16 186 weeks of HFD feeding, mice were sacrificed under fasting conditions, plasm, adipose 187 and liver of mice were collected for subsequent examination. 188

189 Cellular and Molecular Studies

Genetic manipulation and metabolic measurement in human and mouse liver cell lines. 190 as well as mouse adipocyte precursor cells, were used to investigate the role of the 191 192 indicated genes in lipid metabolism. Luciferase reporter assays, CUT & Tag, DNA pull-down assays, and subsequent mass spectrometry were employed to study the 193 transcriptional regulatory capacity of the indicated SNP and its underlying 194 mechanisms. Quantitative PCR and Western blot analyses were performed to assess 195 gene expression at the mRNA and protein levels. Detailed information on the 196 197 materials and protocols used in the aforementioned studies is provided in the Supplementary Materials. 198

199 Statistics

The clinical statistical analyses were performed using SPSS 26.0 software (IBM Corp., 200 Armonk, NY, United States). The normally distributed data are presented as the means 201 and standard deviation; skewed data are presented as the median (IQR), and 202 categorical data are presented as the number (percentage). Differences in the baseline 203 characteristics among different OSA severity degree groups were examined using 204 205 one-way analysis of variance (ANOVA), non-parametric Kruskal–Wallis H test, or χ^2 tests according to the type of data distribution. Baseline characteristics also tested by 206 the polynomial linear trend test for continuous variables and the linear-by-linear 207 association test for dichotomous variables. 208

For GWAS of OSA-related traits, the quantitative phenotypic variables were analyzed by linear regression under an additive genetic model after adjusting for age, sex, cigarette consumption, and alcohol consumption. Logistic regression analyses were performed to evaluate the relationship between polymorphisms and categorical variables.

For other statistical analysis, the results were presented as the mean \pm SEM. Statistical significance among multiple groups was analyzed by one-way ANOVA, followed by Student's t test using Prism 8 (GraphPad Software, Inc.) to compare the results between two groups. *P* < 0.05 was considered to be statistically significant.

218 **Results**

GWAS revealed novel genetic loci associated with serum lipid levels in OSA patients

To better elucidate the genetic factors underlying metabolic abnormalities in individuals with OSA, we performed a GWAS using SSHS cohort focusing on four serum lipid traits including total cholesterol (CHOL), triglyceride (TRIG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and identified 18 genome-wide significant loci ($p < 5 \times 10^{-8}$) (Fig. 1a-1d).

Among them, 2 loci (rs3832016, and rs80246393) were identified for CHOL; 9 loci
(rs80266524, rs57539228, rs117362525, rs151299191, rs147511495, rs651821,
rs34528262, rs79929907, and rs483082) were identified for TRIG; 2 loci (rs12740374,
and rs72654473) were identified for LDL-C; and the rest 5 loci (rs115849089,
rs651821, rs12149545, rs3786247, and rs3745683) were identified for HDL-C (Table
1).

232 Further analysis revealed no significant correlations between these loci and OSA 233 respiratory events, blood oxygen saturation, or sleep architectures (Supplementary Fig. S1a - S1b). However, several loci demonstrated extensive associations with various 234 metabolic traits. Notably, rs72654473 was closely associated with LDL-C, ApoB, and 235 236 ApoE levels, while rs651821 showed strong associations with TRIG, HDL-C, and ApoE levels (Fig. 1e). The annotation and expression quantitative trait locus (eQTL) 237 analysis of the 18 SNPs revealed that several loci or risk genes are widely 238 characterized in several other GWAS of lipid traits, including APOA5 (rs651821), 239 240 APOE (rs72654473), APOC1 (rs483082), CELSR2 (rs3832016, rs12740374), CETP (rs12149545) and LIPG (rs3786247). Furthermore, eight SNPs, including the 241 CHOL-associated SNP (rs80246393) and TRIG-associated SNPs (rs80266524, 242 rs57539228, rs117362525, rs147511495, rs151299191, rs34528262, and rs79929907), 243 along with their affected genes, have not been previously reported in relation to lipid 244 metabolism (Supplementary Table S1). 245

The annotation analysis showed that rs3745683 is located in the upstream region of *ANGPTL8* gene (Fig. 1f). Clinical data reveal elevated levels of ANGPTL8 expression in the serum of OSA patients (Fig. 1g, 1h), and previous studies has also suggested that ANGPTL8 expression can serve as an indicator of OSA improvement following weight loss surgery [15], Consequently, we have selected rs3745683 for our subsequent investigations.

A subpopulation of 4,692 individuals from SSHS cohort, compromising 658 healthy controls, 258 Mild OSA, 969 Moderate OSA, 2,852 Severe OSA, were analyze to further validate the association of rs3745683 and serum lipid levels (Supplementary

255 Table S2). The results revealed a significant association between the rs3745683 (G>A) variant and lower serum HDL-C, CHOL, ApoA and non HDL-C levels, which is a 256 well characterized risk factor for CVD (Fig. 1i-1l, Supplementary Fig. S1g, S1h). 257 Stratifying by OSA severity and adjusting for age, gender, cigarette consumption, and 258 alcohol consumption, multiple linear regression analysis under an additive model 259 revealed a significant inverse association (p < 0.05) between the rs3745683 and serum 260 levels of HDL-C, CHOL, and ApoA across the three groups and the total population 261 262 (Fig. 1m, 1n, Supplementary Table S3). Furthermore, compared to the non OSA group $(\beta = -0.037, p = 0.018)$, rs3745683 exhibited a more pronounced regulatory effect on 263 HDL-C levels in the moderate OSA group ($\beta = -0.044$, $p = 4.21 \times 10^{-4}$) (Fig. 1m, 264 Supplementary Table S3). Propensity score matching analysis, which accounted for 265 differences in sample size, confirmed that rs3745683 remained significantly 266 associated with serum HDL-C levels in the moderate OSA group (p = 0.004) (Fig. 1m, 267 Supplementary Tables S4, S5). In summary, data from clinical samples further 268 validated the strong correlation between rs3745683 and lipid traits. 269

Functional impact of SNP rs3745683 on transcriptional activity and its role in modulating lipid metabolism through ANGPTL8 expression

The locus annotation shows that rs3745683 is located 1,774 bp upstream of the 272 transcription start site (TSS) of ANGPTL8 and within the 14th intron of DOCK6 (Fig. 273 274 2a). Analysis of Ensembl data revealed its localization within an active region associated with transcriptional regulation (Fig. 2a). Furthermore, eQTL analysis from 275 GTEx Portal Database demonstrated a significant correlation between the expression 276 of *DOCK6* and rs3745683 in various tissues, such as Adipose Subcutaneous ($\beta = 1.0$, 277 $p = 1.3 \times 10^{-35}$), Artery Tibial ($\beta = 1.2, p = 2.8 \times 10^{-54}$), and Esophagus Muscularis ($\beta = 1.2, p = 2.8 \times 10^{-54}$) 278 1.1, $p = 7.8 \times 10^{-36}$). Additionally, in Artery Tibial ($\beta = -0.29$, $p = 1.4 \times 10^{-3}$) and 279 adipose naive ($\beta = -0.56$, $p = 2.1 \times 10^{-3}$), expression of *ANGPTL8* was also found to be 280 associated based on Ensembl database (Supplementary Table S6). Therefore, we 281 282 hypothesize that rs3745683 may influence the transcriptional activity of this chromosomal region. To address this hypothesis, we cloned DNA fragments of 1,200 283

bp containing the SNP into the 5' end of a luciferase reporter gene (Fig. 2b, 284 Supplementary Table S7). Luciferase activity was subsequently assessed in multiple 285 lipid metabolism-related cell lines with reference allele of rs3745683, including 286 human hepatocytes (HepG2, LO2), mouse hepatocytes (AML12), and mouse 287 preadipocytes (Supplementary Fig. S2a, S2b). Remarkably, the results consistently 288 demonstrated a significant increase in luciferase activity associated with the 289 SNP-linked DNA fragments across different cell types. Furthermore, in comparison to 290 291 the reference allele construct, the alternative construct significantly decreased transcriptional activity in all four cell lines (Fig. 2c-2f). These findings provide 292 compelling evidence supporting the notion that rs3745683 may have a functional 293 impact on transcriptional activity in relevant cellular contexts. 294

295 Given the potential concurrent impact of rs3745683 on the expression of DOCK6 and ANGPTL8, our investigation aimed to elucidate the key genes influenced by 296 rs3745683 in the context of metabolic dysregulation. Previous studies have already 297 298 established ANGPTL8, which highly expressed in liver and adipose tissue 299 (Supplementary Fig. S3a), as a pivotal regulator of lipid metabolism. Our comparative analysis of ANGPTL8 expression in the serum of individuals carrying different alleles 300 of rs3745683 revealed that homozygous individuals (n=31) carrying the alternative 301 allele (A) exhibited significantly reduced levels of ANGPTL8 in their serum 302 303 compared to both homozygous (n=39) and heterozygous individuals (n=56) with the reference allele (G) (Fig. 3a). Furthermore, CRISPR/Cas9 technology was used to 304 conducted separate deletions of Angptl8 in both mouse hepatocyte AML12 cells and 305 306 adipocytes (Fig. 3b, 3c). Compared to wildtype control, the formation of lipid droplets and TRIG content were significantly decreased in Angptl8-sgRNAs transfected cells 307 (Fig. 3d-3g), suggesting that *Angptl8* was required for triglyceride synthesis in both 308 309 hepatocytes and adipocytes. Furthermore, we systematically excluded the involvement of Dock6 deficiency in the observed TRIG synthesis changes 310 (Supplementary Fig. S3b-S3d). As a consequence, we have substantiated that the SNP 311 exerts its influence on lipid metabolism through the modulation of ANGPTL8 312

313 expression.

Identification of transcription factors YBX1, YBX2, PCBP1, and PCBP2 that bound to proximal sequence of rs3745683

To investigate whether rs3745683 influences the binding of adjacent DNA fragments 316 317 to transcription factors or chromatin factors, biotin-labeled DNA probes, designed to mimic the DNA fragments associated with the SNP reference (G) and alternative (A) 318 319 alleles, were synthesized at a length of 50 base pairs (bp) (Fig. 4a). Following incubation with HepG2 nuclear extracts, the resulting precipitates were subjected to 320 streptavidin-based affinity chromatography. Subsequently, the protein bands 321 specifically enriched in the precipitates containing the reference allele probe were 322 subjected to mass spectrometry (MS) analysis. Through this method, we successfully 323 identified the specific enrichment of transcription factors YBX1, YBX2, PCBP1, and 324 PCBP2, collectively termed YYPP (Fig. 4b, 4c). 325

We further validated the affinity precipitation results by conducting experiments in 326 327 HepG2, which revealed a stronger enrichment of the transcription factor YBX1, PCBP1 and PCBP2 with the reference allele probe (Fig. 4d). Previous studies have 328 indicated YYPP as a tightly bound protein complex [31-33], and YBX1 can directly 329 bind to DNA sequences with a binding motif represented by (5'-TGTACCATC-3') 330 (Fig. 4f). Through sequence comparison, we identified that the proximal sequence to 331 rs3745683 conforms to the binding motif characteristic of YBX1. Moreover, a further 332 analysis of the upstream transcriptional regulatory sequence of mouse Angptl8 333 revealed the presence of multiple YBX1 binding motifs (Fig. 4e-4g). Therefore, we 334 335 hypothesize that YYPP are required for the transcriptional regulation of ANGPTL8 expression cross species. 336

337

YBX1 responds to insulin signaling and regulates ANGPTL8 expression

Intermittent hypoxia and elevated insulin levels are two pathophysiological features in individuals with OSA, therefore, we investigated whether these factors affect the expression of *ANGPTL8* through YYPP [34]. Despite the ability of hypoxia

stimulation to induce an increase in ANGPTL8 expression (Supplementary Fig. S4k), 341 the core transcription factor of hypoxia signaling, hypoxia inducible factor 1 subunit 342 alpha (HIF1a), was not enriched in the rs3745683 DNA fragment. Furthermore, Co-IP 343 experiments did not reveal any interaction between HIF1a and YYPP (Supplementary 344 S4a-S4d). Additionally, luciferase reporter assays demonstrated that 345 Fig. overexpression of YYPP did not alter the transcription of HIF1a-responsive reporters 346 (Supplementary Fig. S4e-S4h). Taken together, our results indicate that hypoxia 347 348 signaling does not regulate ANGPTL8 expression through the YYPP and rs3745683.

Since the little effect of HIF1a on ANGPTL8 expression by rs3745683, we focus on 349 insulin signaling. Within our OSA cohort, we observed a substantial elevation in 350 serum insulin levels and ANGPTL8 levels (Fig. 1g, 1h, Fig. 5a-5b). We conducted 351 further analysis on a subpopulation of 123 individuals from the SSHS cohort to clarify 352 the relationship between ANGPTL8 and insulin levels. Considerate the influence of 353 insulin resistance, we then stratified HOMA-IR into quartiles corresponding to a 354 355 HOMA-IR of Q1 (n = 30, HOMA-IR < 1.39), Q2 (n = 30, 1.39 \leq HOMA-IR < 2.00), 356 Q3 (n = 32, 2.00 \leq HOMA-IR < 2.83), Q4 (n = 31, HOMA-IR \geq 2.83). Linear regression analysis showed a significantly positive correlation ($R^2 = 0.1775$, p =357 0.0203) between serum ANGPTL8 and fasting insulin levels in group Q1 which 358 performed a better insulin sensitivity compared to other groups. While, within the 359 360 insulin resistance getting worse, the correlation between ANGPTL8 and insulin level getting weak (Fig. 5c). Collectively, these results implied that insulin facilitated 361 ANGPTL8 expression and the decrease of sensitivity of insulin signaling pathway 362 inhibited this progress. 363

Additionally, both preadipocytes and hepatocytes demonstrated a significant upregulation of *ANGPTL8* expression in response to insulin signaling (Fig. 5d). To investigate whether the transcription factors YYPP mediate insulin regulation of *ANGPTL8*, we utilized CRISPR/Cas9 technology to perform targeted silence of YYPP expression in preadipocytes and AML12 cells (Fig. 5e, 5f). The results unequivocally showed that the depletion of YYPP in both cell types resulted in a substantial

reduction in *ANGPTL8* expression and TRIG contents (Fig. 5g-5l). Consistently,
overexpression of YYPP significantly increased *ANGPTL8* expression in all of four
adipose and hepatic cell lines (Fig. 5m). Furthermore, luciferase reporter assays
provided compelling additional evidence, supporting the notion that the loss of YYPP
significantly impaired the transcriptional regulatory activity of *ANGPTL8* (Fig. 5n,
50).

376 We then examined the cellular localization of YYPP in preadipocytes. In the untreated state, PCBP1 and PCBP2 were localized in the cell nucleus, whereas YBX1 and 377 YBX2 were predominantly found in the cytoplasm (Fig. 6a). Upon insulin stimulation, 378 YBX1 exhibited increased expression and translocated from the cytoplasm to the 379 nucleus (Fig. 6a-6b). To investigate the signaling mechanisms involved in insulin 380 381 stimulation, we examined the downstream activation of the PI3K-AKT and ERK MAP kinase pathways [35]. We used specific inhibitors, LY294002 and PD98059, to 382 inhibit the PI3K-AKT and ERK MAP kinase pathways, respectively. Notably, 383 384 inhibition of the PI3K-AKT pathway significantly reduced the nuclear translocation 385 of YBX1, indicating that AKT kinase activity is crucial for nuclear YBX1 expression 386 (Fig. 6c). This finding is supported by previous studies reporting AKT-mediated phosphorylation of YBX1 at Ser102 [36]. 387

To validate this, we performed immunoblot experiments, which demonstrated clear 388 389 insulin-induced phosphorylation of YBX1 at the Ser102 site across different cell types. Peak phosphorylation and subsequent nuclear translocation of YBX1 were observed 390 30 minutes after insulin treatment (Fig. 6b, 6d-6g). Furthermore, through 391 immunoprecipitation experiments, we confirmed the protein interaction between 392 AKT1 and YBX1, but did not observe interactions between YBX1 and AKT2 or 393 394 AKT3 (Fig. 6h, Supplementary Fig. S4i, S4j). Collectively, these findings provide strong evidence that the insulin-AKT1 signaling pathway promotes the nuclear 395 translocation of YBX1 through its phosphorylation. 396

To validate our observations, we generated two mutants of YBX1 at Ser102: the non-phosphorylatable Ser102Ala (S102A) and the phospho-mimicking Ser102Asp

(S102D) mutants, along with mutants at other serine residues potentially involved in 399 phosphorylation (Fig. 7a, Supplementary Fig. S5a). Intriguingly, the S102D and 400 S176A mutants consistently exhibited nuclear localization even in the absence of 401 insulin stimulation (Fig. 7a, Supplementary Fig. S5a). In Ybx1-sgRNA transfected 402 cells, the S102D, S176A, and S176D mutants restored the expression of Angptl8 (Fig. 403 7b, 7c). In wildtype adipocytes and AML12 cells, transfection with the S102D, S176A, 404 and S176D mutants significantly increased Angptl8 expression and led to a notable 405 406 elevation of TRIG content within the cells (Fig. 7d-7g).

Furthermore, we employed Cleavage Under Targets and Tagmentation (CUT & Tag) and real-time quantitative PCR (RT-qPCR) using an anti-H3K27Ac antibody to assess the transcriptional activity of the rs3745683 locus proximal region. Results showed that insulin increased the enrichment of the rs3745683 locus proximal region in HepG2 cells; however, this effect was inhibited by YBX1 deficiency (Fig. 7h). Taken together, these results indicate that YBX1 is essential for *Angptl8* expression, and the phosphorylation of YBX1 at Ser102 is critical for initiating this process.

We also performed RNA sequencing to analyze the gene expression profiles in Ybx1-414 and Angptl8- deficient AML12 cells (Supplementary Fig. S5b-S5c). Compared to the 415 control group, 4,958 genes showed significant changes in expression (p < 0.05) in the 416 Ybx1- deficient cells, and 7,982 genes were significantly differentially expressed in 417 the Angptl8- deficient cells. Among these differentially expressed genes (DEGs), 418 1,389 genes were up-regulated in both groups (p < 0.05, log2FoldChange > 0), and 419 1,472 genes were down-regulated in both groups (p < 0.05, log2FoldChange < 0) (Fig. 420 421 7i-7i). Furthermore, functional enrichment analysis revealed that these DEGs were associated with lipid metabolism-related biological processes, such as "lipid 422 homeostasis" and "cholesterol metabolic process" (Fig. 7k, Supplementary Fig. S5d). 423 These results indicate similar gene expression profiles in Ybx1- and Angptl8-deficient 424 hepatocytes, strongly suggesting that Ybx1 affects lipid metabolism by regulating 425 Angptl8 expression. 426

427 YBX1 regulates Angptl8 expression and lipid metabolism in mouse liver

To further explore the effect on lipid metabolism of *Ybx1 in vivo*, we therefore performed the knock-down of *Ybx1* in liver by delivering AAV2/8 containing *Ybx1*-shRNA (AAV-*Ybx1*-shRNA) in C57BL/6J male mice, achieving approximately 80% specific deficiency in *Ybx1* levels in liver (Fig. 8a-8d). Consistently, we also observed about 20% and 50% decrease of *Angpt18* in mRNA level and protein level, respectively, in *Ybx1*-deficient mouse livers (Fig. 8b-8d).

434 We conducted a 16-week high-fat diet intervention on two genotypes of mice and 435 examined their metabolic parameters. We found that the knockdown of Ybx1 in the liver did not significantly affect the overall metabolic characteristics of the mice, 436 including body weight, food intake, fat mass, lean mass, as well as the weights of 437 438 metabolic organs including liver, inguinal white adipose tissue (iWAT), epididymal 439 white adipose tissue (eWAT), and brown fat (Fig. 8e-8g). Additionally, under fasting conditions, there were no significant changes in serum TRIG and CHOL levels (Fig. 440 8i-8j). Meanwhile, mice of both genotypes after 12 weeks HDF treatment performed 441 442 similarly in glucose tolerance test under fasting state (Fig. 8h). However, the levels of 443 TRIG and CHOL were significantly decreased in Ybx1-deficient mouse liver, 444 suggesting that Ybx1 is required for the lipid synthesis in livers (Fig. 8i-8k). A further RNA-seq analysis showed the deficiency of YBX1 in mouse liver significantly 445 decreased Angptl8 mRNA level (log2Foldchange = -1.114, p = 0.002). The functional 446 447 enrichment analysis showed that these significantly changed DEGs were associated with nucleotide or lipid metabolism-related biological processes, such as "nucleotide 448 metabolic process" and "negative regulation of lipid biosynthetic process" (Fig. 449 81-8m). These in vivo results showed that deficiency of Ybx1 decreases ANGPTL8 450 451 expression in both mRNA and protein levels, and further improve TRIG and CHOL accumulation in liver. 452

To further investigate whether *YBX1* and its associated cofactors are involved in the regulation of human metabolism and the occurrence of metabolic diseases, we conducted an in-depth exploration using the EBI Metabolomics-related GWAS datasets. Unfortunately, our analysis did not identify any genetic variations in *YBX1*

significantly associated with various metabolic traits ($p < 5 \times 10^{-5}$) (Fig. 8n). However, 457 we did observe a genome-wide significant association between the non-coding SNP 458 rs180915454 in YBX2 and a decrease in total cholesterol ($\beta = -0.213$, $p = 1.20 \times 10^{-70}$) 459 (Fig. 80). Additionally, the missense variant rs8069533 (p. Ser63Pro) in YBX2 showed 460 a genome-wide significant association with an increase in total cholesterol ($\beta = 0.011$, 461 $p = 5.81 \times 10^{-18}$) (Fig. 80). Also, we identified an upstream SNP rs6546568 of *PCBP1* 462 is a genome-wide significant variant of total cholesterol ($\beta = 0.016$, $p = 2.54 \times 10^{-15}$) 463 464 (Fig. 8p). These genetic correlation data further suggest the significant involvement of YBX1 and its associated factors in the regulation of human metabolism. 465

466 Collectively, our comprehensive findings shed light on the intricate molecular
467 mechanisms involved in YBX1-mediated regulation of *ANGPTL8* expression.

468 **Discussion**

A large number of studies, including meta-analyses have firmly established the 469 profound impact of OSA, not only significantly elevating the risk of adverse health 470 471 outcomes but also independently serving as a predictive factor for overall and cardiovascular mortality [37]. Additionally, individuals afflicted with OSA exhibit an 472 enhanced susceptibility to the development of dyslipidemia and insulin resistance [38]. 473 A twin study has underscored the substantial hereditary component contributing to the 474 emergence of dyslipidemia in OSA patients [39]. Recent genetic investigations 475 conducted within OSA populations have shed light on the role played by genetic 476 variations, including those within the leptin receptor and ApoA5, in the manifestation 477 of dyslipidemia among OSA patients [40, 41]. 478

479 Nevertheless, the precise mechanisms by which OSA instigates disruptions in lipid 480 metabolism have remained largely uncharted. Our study has brought to the forefront a 481 noteworthy correlation between genetic variations in the endocrine hormone 482 ANGPTL8 and lipid irregularities in OSA patients. Moreover, we have observed a 483 significant elevation in ANGPTL8 levels in OSA patients, with both of OSA's 484 pathophysiological hallmarks, intermittent hypoxia and insulin resistance,

485 contributing to an upregulation in ANGPTL8 expression. We have further elucidated how the insulin-AKT1-YBX1 pathway, by fostering the expression of ANGPTL8, 486 subsequently amplifies lipid synthesis in the liver and adipose tissues. Our findings 487 serve to enhance our comprehension of the molecular mechanisms through which 488 OSA induces abnormalities in lipid metabolism. 489

490 Our research, conducted at both the human genetic and molecular cellular levels, 491 unambiguously supports the pivotal role of ANGPTL8, a serum hormone, in the 492 context of dyslipidemia in OSA. This observation aligns with the recent body of 493 research that underscores the extensive yet highly conserved role of ANGPTL8 in metabolic regulation. ANGPTL8, a serum hormone secreted by both the liver and 494 adipose tissues, further modulates the glycemic and lipidic processes in muscle, liver, 495 496 and adipose tissues through endocrine mechanisms. Notably, recent studies by Siyu chen et al. have revealed that ANGPTL8 can interact with hepatic surface receptor 497 498 PirB, thereby influencing the expression of circadian genes in hepatocytes, with 499 implications for hepatic metabolism [42]. Moreover, multiple investigations have 500 underscored the pivotal role of ANGPTL8 in the onset and progression of various 501 metabolic disorders. For instance, Zongli Zhang and colleagues unveiled that ANGPTL8 exerts a promotive effect on the development of non-alcoholic fatty liver 502 disease [16]. Targeted strategies aimed at inhibiting ANGPTL8 have already 503 504 demonstrated promising effects in models of dyslipidemia in humanized mice [16]. Collectively, our research also suggests that the targeted inhibition of ANGPTL8 may 505 506 hold potential therapeutic value in addressing metabolic syndrome.

508 509 510

507 Y-box binding protein 1 (YBX1), a member of the DNA- and RNA-binding protein family, has garnered significant attention due to its involvement in malignant cell transformation, tumor aggressiveness, and its potential as a therapeutic target in cancer and inflammation [43]. Initially recognized as a DNA transcription factor for nucleotide sequence 511 its binding to a DNA known as the Y-box (5'-CTGATTGGC/TC/TAA-3') located in gene promoters [44], YBX1 has since been 512 attributed to a range of functions, including DNA repair, pre-mRNA splicing, 513

translation, and packaging [45]. Recent studies have unveiled YBX1's ability to influence gene expression both within and outside the context of the Y-box sequence. Notably, DNA pulldown and LC–MS analyses conducted in our study have indicated that YBX1, in concert with YBX2, PCBP1, and PCBP2, represents potential transcription factors binding to the rs3745683 region. Furthermore, the binding affinities of YBX1, PCBP1, and PCBP2 to rs3745683 (G>A) are diminished in the presence of this genetic variation.

521 Emerging research has illuminated YBX1's role not only in tumorigenesis but also in the regulation of thermogenic gene expression in adipocytes and the transformation of 522 white adipose tissue into brown adipose tissue [46, 47]. Another study has 523 demonstrated that YBX1 promotes brown adipogenesis and thermogenic activity 524 525 through PINK1/PRKN-mediated mitophagy [48]. These findings underscore the multifaceted functions of YBX1 in adipose tissue biology. Our study, in which we 526 employed CRISPR/Cas9 to generate TFs-deficiency adipocyte and hepatocyte cell 527 528 lines, revealed that the depletion of YBX1 significantly reduced Angptl8 expression, 529 intracellular lipid droplets, and triglyceride content. Furthermore, our prior research 530 has shown that serum fasting insulin levels are positively correlated with the severity of OSA [49]. Thus, it is reasonable to infer that YBX1, a responsive factor to insulin 531 signaling, exerts regulatory control over ANGPTL8 expression by binding to the 532 533 rs3745683 region, thereby influencing adipocyte lipid metabolism in OSA. Nevertheless, it is important to note that our study is grounded mostly in vitro 534 experiments, and further in vivo investigations are imperative for a comprehensive 535 understanding of these mechanisms. 536

537 CRediT authorship contribution statement

Yuenan Liu: Methodology, Investigation, Formal analysis, Data analysis,
Writing-original draft. Haolin Yuan: Investigation, Validation. Anzhao Wang:
Investigation, Validation. Shengming Wang: Data analysis. Xu Xu: Funding
acquisition, Methodology, Investigation. Junhui Hu: Investigation. Jinhong Shen:
Funding acquisition, Methodology, Investigation. Yiming Hu: Funding acquisition,

543 Methodology, Investigation. Xinyi Li: Funding acquisition, Investigation. Niannian Li: 544 Methodology, Data analysis. Zhenfei Gao: Methodology, Investigation. Xiaoxu Zhang: Investigation. Xiaoman Zhang: Investigation. Huajun Xu: Methodology. Hongliang Yi: 545 Funding acquisition, Methodology. Jian Guan: Funding acquisition, Supervision. 546 Zhiqiang Li: Methodology, Supervision. Yongxu Zhao: Funding acquisition, 547 Methodology, Investigation, Supervision. Shankai Yin: Funding acquisition, 548 Supervision, Methodology, Writing-original draft. Feng Liu: Funding acquisition, 549 550 Methodology, Supervision, Writing-original draft.

551 Dec

Declaration of competing interest

552 All authors in this study declare no competing interests.

553 Declaration of generative AI and AI-assisted technologies in the writing process

554 During the preparation of this work the authors used OpenAI's tool ChatGPT in order 555 to improve the English grammar. After using this tool, the authors reviewed and 556 edited the content as needed and take full responsibility for the content of the 557 publication.

558

559 Data Availability Statement

Full summary statistics for the gwas study of SSHS can be accessed from 560 https://figshare.com/ (DOI: 10.6084/m9.figshare.20033246) and Bio-X institutes 561 website (http://analysis.bio-x.cn/gwas/). The raw genetic data for each individual from 562 our analyses could also be accessed under the Data Access Agreement 563 564 (https://figshare.com/, DOI: 10.6084/m9.figshare.20033243 and http://galaxy.bio-x.cn/library/list#folders/Ff2db41e1fa331b3e). Additional raw data 565 can be obtained upon request from the authors. 566

- 567
- 568

569 Acknowledgements

We would like to thank Professor Junli Liu from Shanghai Diabetes Institute, 570 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University 571 Affiliated Sixth People's Hospital for his assistance in indirect experiment. This study 572 was also supported by grants-in-aid from Ministry of Science and Technology of the 573 People's Republic of China (2021ZD0201900), National Natural Science Foundation 574 of China (81971240, 82070824, 82171125, 81970869, 81970870, 82271153, 575 82000967, 82101205, 82100105, 82301291, 82300962), Shanghai Municipal 576 577 Commission of Science and Technology (Grant No.18DZ2260200), the Interdisciplinary Program of Shanghai Jiao Tong University (YG2023LC11), Youth 578 Innovation Promotion Association of CAS (2023289), Shanghai Sailing Program 579 grant (23YF1431900). The funding sources had no role in design, conduct, analysed, 580 and interpreted of this study. 581

- 582 Appendix Supplementary data
- 583 Supplementary Figures
- 584 Supplementary Context
- 585 Supplementary Materials

586 **References**

- [1]. Åberg, F., et al., Alcohol consumption and metabolic syndrome: Clinical and
 epidemiological impact on liver disease. J Hepatol, 2023. 78(1): p. 191-206. DOI:
 10.1016/j.jhep.2022.08.030.
- 590
- [2]. Mesarwi, O.A., R. Loomba, and A. Malhotra, Obstructive Sleep Apnea, Hypoxia,
 and Nonalcoholic Fatty Liver Disease. Am J Respir Crit Care Med, 2019. 199(7): p.
 830-841. DOI: 10.1164/rccm.201806-1109TR.
- 594
- [3]. Gaines, J., et al., Obstructive sleep apnea and the metabolic syndrome: The road
 to clinically-meaningful phenotyping, improved prognosis, and personalized
 treatment. Sleep Med Rev, 2018. 42: p. 211-219. DOI: 10.1016/j.smrv.2018.08.009.
- 599 [4]. Xu, S., et al., The association between obstructive sleep apnea and metabolic
 600 syndrome: a systematic review and meta-analysis. BMC Pulm Med, 2015. 15: p. 105.
 601 DOI: 10.1186/s12890-015-0102-3.
- 602

603 [5]. Trzepizur, W., et al., Sleep Apnea-Specific Hypoxic Burden, Symptom Subtypes, and Risk of Cardiovascular Events and All-Cause Mortality. Am J Respir Crit Care 604 Med, 2022. 205(1): p. 108-117. DOI: 10.1164/rccm.202105-1274OC. 605 606 [6]. Guo, C., et al., ANGPTL8 in metabolic homeostasis: more friend than foe? Open 607 Biol, 2021. 11(9): p. 210106. DOI: 10.1098/rsob.210106. 608 609 [7]. Zhang, R. and A.B. Abou-Samra, Emerging roles of Lipasin as a critical lipid 610 regulator. Biochem Biophys Res Commun, 2013. 432(3): p. 401-5. DOI: 611 10.1016/j.bbrc.2013.01.129. 612 613 [8]. Meng, M., et al., Zinc finger protein ZNF638 regulates triglyceride metabolism 614 615 via ANGPTL8 in an estrogen dependent manner. Metabolism, 2024. 152: p. 155784. DOI: 10.1016/j.metabol.2024.155784. 616 617 [9]. Guo, T., et al., Association of the angiopoietin-like protein 8 rs2278426 618 polymorphism and several environmental factors with serum lipid levels. Mol Med 619 620 Rep, 2015. 12(3): p. 3285-3296. DOI: 10.3892/mmr.2015.3825. 621 [10]. Crujeiras, A.B., et al., Interplay of atherogenic factors, protein intake and 622 betatrophin levels in obese-metabolic syndrome patients treated with hypocaloric 623 diets. Int J Obes (Lond), 2016. 40(3): p. 403-10. DOI: 10.1038/ijo.2015.206. 624 625 [11]. Luo, M. and D. Peng, ANGPTL8: An Important Regulator in Metabolic 626 Disorders. Front Endocrinol (Lausanne), 2018. 9: 169. DOI: 627 p. 10.3389/fendo.2018.00169. 628 629 [12]. Wang, D., et al., Angiopoietin-Like Protein 8/Leptin Crosstalk Influences 630 631 Cardiac Mass in Youths With Cardiometabolic Risk: The BCAMS Study. Front 632 Endocrinol (Lausanne), 2021. 12: p. 788549. DOI: 10.3389/fendo.2021.788549. 633 [13]. Chen, X., et al., Circulating betatrophin levels are increased in patients with type 634 2 diabetes and associated with insulin resistance. J Clin Endocrinol Metab, 2015. 635 636 100(1): p. E96-100. DOI: 10.1210/jc.2014-2300. 637 [14]. Al-Terki, A., et al., Increased Level of Angiopoietin Like Proteins 4 and 8 in 638 People With Sleep Apnea. Front Endocrinol (Lausanne), 2018. 9: p. 651. DOI: 639 10.3389/fendo.2018.00651. 640 641 [15]. Song, Z., et al., Decreased serum betatrophin may correlate with the 642 improvement of obstructive sleep apnea after Roux-en-Y Gastric Bypass surgery. Sci 643 644 Rep, 2021. 11(1): p. 1808. DOI: 10.1038/s41598-021-81379-1. 645 [16]. Zhang, Z., et al., ANGPTL8 accelerates liver fibrosis mediated by HFD-induced 646

inflammatory activity via LILRB2/ERK signaling pathways. J Adv Res, 2023. 47: p.
41-56. DOI: 10.1016/j.jare.2022.08.006.

649

[17]. Lee, Y.H., et al., Association between betatrophin/ANGPTL8 and non-alcoholic
fatty liver disease: animal and human studies. Sci Rep, 2016. 6: p. 24013. DOI:
10.1038/srep24013.

653

[18]. Chen, J., et al., In vivo targeted delivery of ANGPTL8 gene for beta cell
regeneration in rats. Diabetologia, 2015. 58(5): p. 1036-44. DOI:
10.1007/s00125-015-3521-z.

657

[19]. DiDonna, N.M., Y.Q. Chen, and R.J. Konrad, Angiopoietin-like proteins and
postprandial partitioning of fatty acids. Curr Opin Lipidol, 2022. 33(1): p. 39-46. DOI:
10.1097/MOL.0000000000798.

661

[20]. Zhang, R. and K. Zhang, An updated ANGPTL3-4-8 model as a mechanism of
triglyceride partitioning between fat and oxidative tissues. Prog Lipid Res, 2022. 85: p.
101140. DOI: 10.1016/j.plipres.2021.101140.

665

[21]. Henneman, P., et al., Genetic architecture of plasma adiponectin overlaps with
the genetics of metabolic syndrome-related traits. Diabetes Care, 2010. 33(4): p.
908-13. DOI: 10.2337/dc09-1385.

669

[22]. Fall, T. and E. Ingelsson, Genome-wide association studies of obesity and
metabolic syndrome. Mol Cell Endocrinol, 2014. 382(1): p. 740-757. DOI:
10.1016/j.mce.2012.08.018.

674 [23]. Aguilera, C.M., J. Olza, and A. Gil, Genetic susceptibility to obesity and
675 metabolic syndrome in childhood. Nutr Hosp, 2013. 28 Suppl 5: p. 44-55. DOI:
676 10.3305/nh.2013.28.sup5.6917.

677

673

[24]. Norris, J.M. and S.S. Rich, Genetics of glucose homeostasis: implications for
insulin resistance and metabolic syndrome. Arterioscler Thromb Vasc Biol, 2012.
32(9): p. 2091-6. DOI: 10.1161/ATVBAHA.112.255463.

681

[25]. Su, X., Y. Cheng, and B. Wang, ANGPTL8 in cardio-metabolic diseases. Clin
Chim Acta, 2021. 519: p. 260-266. DOI: 10.1016/j.cca.2021.05.017.

684

[26]. Cannon, M.E., et al., Trans-ancestry Fine Mapping and Molecular Assays
Identify Regulatory Variants at the ANGPTL8 HDL-C GWAS Locus. G3 (Bethesda),
2017. 7(9): p. 3217-3227. DOI: 10.1534/g3.117.300088.

688

[27]. Hanson, R.L., et al., The Arg59Trp variant in ANGPTL8 (betatrophin) is
 associated with total and HDL-cholesterol in American Indians and Mexican

Americans and differentially affects cleavage of ANGPTL3. Mol Genet Metab, 2016.
118(2): p. 128-37. DOI: 10.1016/j.ymgme.2016.04.007.

[28]. Lee, Y.H., et al., APOE and KLF14 genetic variants are sex-specific for low
high-density lipoprotein cholesterol identified by a genome-wide association study.
Genet Mol Biol, 2022. 45(1): p. e20210280. DOI:
10.1590/1678-4685-GMB-2021-0280.

[29]. Quagliarini, F., et al., Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci U S A, 2012. 109(48): p. 19751-6. DOI: 10.1073/pnas.1217552109.

[30]. Xu, H., et al., Genome-Wide Association Study of Obstructive Sleep Apnea and Objective Sleep-related Traits Identifies Novel Risk Loci in Han Chinese Individuals. Am J Respir Crit Care Med, 2022. 206(12): p. 1534-1545. DOI: 10.1164/rccm.202109-2044OC.

[31]. Funke, B., et al., The mouse poly(C)-binding protein exists in multiple isoforms
and interacts with several RNA-binding proteins. Nucleic Acids Res, 1996. 24(19): p.
3821-8. DOI: 10.1093/nar/24.19.3821.

 [32]. Rosenbluh, J., et al., Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in β-Catenin-Active Cancers. Cell Syst, 2016. 3(3): p. 302-316.e4. DOI: 10.1016/j.cels.2016.09.001.

[33]. Huttlin, E.L., et al., Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell, 2021. 184(11): p. 3022-3040.e28. DOI: 10.1016/j.cell.2021.04.011.

[34]. Dempsey, J.A., et al., Pathophysiology of sleep apnea. Physiol Rev, 2010. 90(1): p. 47-112. DOI: 10.1152/physrev.00043.2008.

[35]. Siddle, K., Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol, 2011. 47(1): p. R1-10. DOI: 10.1530/JME-11-0022.

[36]. Alkrekshi, A., et al., A comprehensive review of the functions of YB-1 in cancer stemness, metastasis and drug resistance. Cell Signal, 2021. 85: p. 110073. DOI: 10.1016/j.cellsig.2021.110073.

[37]. Fu, Y., et al., Meta-analysis of all-cause and cardiovascular mortality in
obstructive sleep apnea with or without continuous positive airway pressure treatment.
Sleep Breath, 2017. 21(1): p. 181-189. DOI: 10.1007/s11325-016-1393-1.

734 [38]. Framnes, S.N. and D.M. Arble, The Bidirectional Relationship Between

735 Obstructive Sleep Apnea and Metabolic Disease. Front Endocrinol (Lausanne), 2018.
736 9: p. 440. DOI: 10.3389/fendo.2018.00440.

737

[39]. Meszaros, M., et al., Obstructive sleep apnea and hypertriglyceridaemia share
common genetic background: Results of a twin study. J Sleep Res, 2020. 29(4): p.
e12979. DOI: 10.1111/jsr.12979.

741

[40]. Popko, K., et al., Frequency of distribution of leptin receptor gene polymorphism in obstructive sleep apnea patients. J Physiol Pharmacol, 2007. 58
Suppl 5(Pt 2): p. 551-61.

745

[41]. Bielicki, P., et al., Impact of polymorphism of selected genes on the diagnosis of
type 2 diabetes in patients with obstructive sleep apnea. Pol Arch Intern Med, 2019.
129(1): p. 6-11. DOI: 10.20452/pamw.4406.

749

[42]. Chen, S., et al., Angptl8 mediates food-driven resetting of hepatic circadian
clock in mice. Nat Commun, 2019. 10(1): p. 3518. DOI:
10.1038/s41467-019-11513-1.

[43]. Lyabin, D.N., I.A. Eliseeva, and L.P. Ovchinnikov, YB-1 protein: functions and
regulation. Wiley Interdiscip Rev RNA, 2014. 5(1): p. 95-110. DOI:
10.1002/wrna.1200.

757

753

[44]. Wolffe, A.P., Structural and functional properties of the evolutionarily ancient
Y-box family of nucleic acid binding proteins. Bioessays, 1994. 16(4): p. 245-51. DOI:
10.1002/bies.950160407.

761

[45]. Ceman, S., R. Nelson, and S.T. Warren, Identification of mouse YB1/p50 as a
component of the FMRP-associated mRNP particle. Biochem Biophys Res Commun,
2000. 279(3): p. 904-8. DOI: 10.1006/bbrc.2000.4035.

765

[46]. Rabiee, A., et al., White adipose remodeling during browning in mice involves
YBX1 to drive thermogenic commitment. Mol Metab, 2021. 44: p. 101137. DOI:
10.1016/j.molmet.2020.101137.

769

[47]. Park, J.H., et al., A multifunctional protein, EWS, is essential for early brown fat
lineage determination. Dev Cell, 2013. 26(4): p. 393-404. DOI:
10.1016/j.devcel.2013.07.002.

773

[48]. Wu, R., et al., RNA-binding protein YBX1 promotes brown adipogenesis and
thermogenesis via PINK1/PRKN-mediated mitophagy. Faseb j, 2022. 36(3): p.
e22219. DOI: 10.1096/fj.202101810RR.

777

778 [49]. Zou, J., et al., Independent relationships between cardinal features of

obstructive sleep apnea and glycometabolism: a cross-sectional study. Metabolism,
2018. 85: p. 340-347. DOI: 10.1016/j.metabol.2017.11.021.
781
782
783
784
785
78ble1. Eighteen Genetic variant loci associated with serum CHOL, TRIG, LDL-C and
786
HDL-C levels in GWAS cohort.

787

| Traits | SNP ID | Chr | A1 | A2 | β | SE | <i>p</i> value | MAF |
|--------|-------------|-----|----|----|----------|----------|--------------------------|---------|
| CHOL | rs3832016 | 1 | С | CT | -0.2278 | 0.03897 | 5.34 × 10 ⁻⁰⁹ | 0.05824 |
| CHOL | rs80246393 | 6 | G | А | 0.5041 | 0.0922 | 4.76 × 10 ⁻⁰⁸ | 0.01101 |
| TRIG | rs80266524 | 1 | С | А | 0.9058 | 0.1648 | 4.06×10^{-08} | 0.01118 |
| TRIG | rs57539228 | 3 | А | G | 0.9427 | 0.1664 | 1.54 × 10 ⁻⁰⁸ | 0.01082 |
| TRIG | rs117362525 | 3 | С | Т | 0.8484 | 0.1514 | 2.22×10^{-08} | 0.01429 |
| TRIG | rs151299191 | 10 | G | А | 0.9586 | 0.1708 | 2.09 × 10 ⁻⁰⁸ | 0.01019 |
| TRIG | rs147511495 | 10 | А | G | 0.9014 | 0.1504 | 2.16 × 10 ⁻⁰⁹ | 0.01373 |
| TRIG | rs651821 | 11 | С | Т | 0.5633 | 0.03756 | 6.22 × 10 ⁻⁵⁰ | 0.2807 |
| TRIG | rs34528262 | 13 | Т | G | 0.9393 | 0.159 | 3.69 × 10 ⁻⁰⁹ | 0.01197 |
| TRIG | rs79929907 | 16 | G | А | 0.779 | 0.1252 | 5.26 × 10 ⁻¹⁰ | 0.01956 |
| TRIG | rs483082 | 19 | Т | G | 0.2837 | 0.04654 | 1.16 × 10 ⁻⁰⁹ | 0.1889 |
| LDL-C | rs12740374 | 1 | Т | G | -0.1934 | 0.03203 | 1.68 × 10 ⁻⁰⁹ | 0.05762 |
| LDL-C | rs72654473 | 19 | А | С | -0.3973 | 0.02821 | 2.73 × 10 ⁻⁴⁴ | 0.07703 |
| HDL-C | rs115849089 | 8 | А | G | 0.04752 | 0.006862 | 4.81 × 10 ⁻¹² | 0.1127 |
| HDL-C | rs651821 | 11 | С | Т | -0.04699 | 0.004766 | 9.34 × 10 ⁻²³ | 0.2807 |

| HDL-C | rs12149545 | 16 | А | G | 0.05475 | 0.005868 | 1.45×10^{-20} | 0.1616 |
|-------|------------|----|---|---|---------|----------|------------------------|--------|
| HDL-C | rs3786247 | 18 | G | Т | 0.02829 | 0.004447 | 2.17×10^{-10} | 0.4083 |
| HDL-C | rs3745683 | 19 | А | G | -0.0316 | 0.004896 | $1.18 	imes 10^{-10}$ | 0.2695 |

| 788 | |
|-----|--|
| 789 | |
| 790 | A1, minor allele; A2, major allele; MAF, minor allele frequency. |
| 791 | |
| 792 | |
| 793 | |
| 794 | Figures |
| 795 | Figure 1 GWAS identified novel genetic loci associated with serum lipid traits in |
| 796 | Han Chinese OSA patients. (a-d) Manhattan plot showing the genome-wide p |
| 797 | values of association with serum CHOL (a), TRIG (b), LDL-C (c), and HDL-C (d). |
| 798 | The red line shows the genome-wide significant threshold of $p < 5 \times 10^{-8}$. (e) Dotplot |
| 799 | presents the associations between indicated variants and the quantitative traits. (f) |
| 800 | Region plot of association between rs3745683 and HDL-C. The purple dot indicates |
| 801 | rs3745683. (g, h) Serum ANGPTL8 levels in OSA patients. (i-l) The comparison of |
| 802 | serum HDL-C (i), CHOL (k), ApoA (j), and non HDL-C (l) levels among three |
| 803 | genotypes of rs3745683. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. (m, n) |
| 804 | Effects of rs3745683(G>A) on serum HDL-C (m), ApoA (m), CHOL (n), and ApoE |
| 805 | (n) among different severity OSA patients. Beta and p value were obtained by linear |
| 806 | regression analysis with or without adjusting for age, gender, cigarette consumption, |
| 807 | and alcohol consumption. |



Figure 2 rs3745683 suppressed transcriptional activity of ANGPTL8 promoter.
(a) Diagram of rs3745683 in ANGPTL8 promoter. (b) Scheme of vector constructs.
(c-f) Mean (sem) transcriptional activity of *ANGPTL8* promoter with reference allele
(G) or alternative allele (A) in AML12 (c), mouse preadipocytes (d), LO2 (e), and
HepG2 (f) cells. The y axis represents the relative luciferase activity.



Figure 3 An essential role of ANGPTL8 in lipogenesis. (a) The comparison of serum ANGPTL8 level among three genotypes of rs3745683. (b, c) Protein levels of ANGPTL8 in *Angptl8*-sgRNA transfected adipocytes (b) and AML12 cells (c). (d) Triglyceride content analysis of *Angptl8*-sgRNA transfected adipocytes differentiated for 6 days. (e) Triglyceride content analysis of *Angptl8*-sgRNA transfected AML12

cells differentiated for 1 day. (f) Oil red staining and Bodipy 493/503 dye staining of 820 Angptl8-sgRNA transfected adipocytes differentiated for 6 days. (g) Oil red staining 821 and Bodipy 493/503 dye staining of Angptl8-sgRNA transfected AML12 cells 822 differentiated for 1 day. 823





Figure 4 Identification of YBX1 as a transcriptional factor of rs3745683 proximal 825

region. (a) DNA probe sequences containing rs3745683(G>A) locus. Highlight 826 indicates the predicted YBX1 DNA binding motif. (b) Coomassie brilliant 827 blue-stained acrylamide gel of a pulldown assay using oligonucleotides containing 828 allele G of rs3745683. (c) Selected proteins in the ref.oligo-biotin precipitate 829 identified by LC-MS analysis. (d) Immunoblots of a pulldown assay using 830 oligonucleotides containing either allele G and A of rs3745683. (e, g) Predicted YBX1

- DNA binding Motif in ANGPTL8 gene among human and mouse. (f) Motif analysis 832
- of YBX1-bound sequence, available at https://jaspar.elixir.no/matrix/UN0139.1/. 833



834

Figure 5 Effects of YYPP on Angptl8 expression and lipid metabolism. (a-b)
Fasting insulin level in OSA patients (a) and correlation between insulin level and
AHI (b). (c) Linear association analysis of serum ANGPTL8 and fasting insulin level
in different HOMA-IR group. (d) *ANGPTL8* mRNA levels in mouse adipocytes,
AML12, LO2, and HepG2 cells following the stimulation of insulin over a 6-h period.

(e-f) Immunoblots of YYPP-sgRNA knockout efficiency in mouse preadipocytes (e) 840 and AML12 cells (f). (g-h) Oil red staining and Bodipy 493/503 dye staining in 841 YYPP-sgRNAs transfected adipocytes differentiated for 6 days (g), and AML12 cells 842 200uM PA treated for 1 day (h). (i-j) Angptl8 mRNA levels in YYPP-sgRNAs 843 transfected mouse adipocytes differentiated for 6 days (i), and AML12 cells 200uM 844 845 PA treated for 1 day (j). (k-l) TRIG content in YYPP-sgRNAs transfected mouse adipocytes differentiated for 6 days (k), and AML12 cells 200uM PA treated for 1 day 846 (I). (m) ANGPTL8 mRNA levels in mouse adipocytes, AML12, LO2, and HepG2 847 cells after overexpression MYC-tagged YYPP for 2 days. (n) Mean (sem) 848 transcriptional activity of ANGPTL8 promoter with reference allele in YYPP 849 deficiency preadipocytes. (0) Transcriptional activity comparison of vector constructs 850 between promoterless and ANGPTL8 promoter with reference allele in YYPP 851 852 deficiency preadipocytes.



Figure 6 Insulin signaling triggers YBX1 phosphorylation and nuclear
translocation through interaction between YBX1 and AKT. (a) Subcellular
localization of YYPP in preadipocytes stimulated by 5µg/mL insulin for 24 h. (b)
Subcellular localization of YBX1 in preadipocytes following the stimulation of
5µg/mL insulin over a 2-h period. (c) Subcellular localization of YBX1 in

preadipocytes which stimulated by $5\mu g/mL$ insulin, $5\mu g/mL$ insulin+ $20\mu M$ LY294002, or $5\mu g/mL$ insulin+ $10\mu M$ PD98059 for 30mins, respectively. (**d-g**) YBX1-S102p levels in mouse preadipocytes (**d**), AML12 (**e**), LO2 (**f**), and HepG2 (**g**) cells following the stimulation of insulin over a 2-h period. (**h**) Co-Immunoprecipitation analysis of $3 \times FLAG$ -YBX1 and AKT1-HA.



Figure 7 The phosphorylation dependent nuclear translocation of YBX1 865 promotes ANGPTL8 expression. (a) Subcellular localization of GFP-tagged YBX1 866 variations (WT, S102A, S102D, S176A, and S176D) in preadipocytes. The nuclei 867 were stained with DAPI. These images were captured at 630 magnification. (b-c) 868 Angptl8 mRNA levels in Ybx1-sgRNA transfected mouse adipocytes (b), and AML12 869 cells (c) which overexpressed 5 YBX1 variations respectively. (d-e) Angptl8 mRNA 870 levels (d), and TRIG content (e) in mouse adipocytes which overexpressed 5 YBX1 871 variations respectively. (f-g) Angptl8 mRNA levels (f) and TRIG content (g) in 872 AML12 cells which overexpressed 5 YBX1 variations respectively. (h) With or 873 without 20µg/mL insulin stimulation, H3K27Ac occupancy analysis of rs3745683 874 proximal region in HepG2 cells by CUT & Tag-qPCR. (i) Venn plot of gene 875 expression profiles in Ybx1-sgRNA and Angptl8-sgRNA AML12 cells, DEG 876 877 thresholds: p < 0.05. (j) DEGs (p < 0.05) in Ybx1-sgRNA and Angptl8-sgRNA AML12 cells. Gray line represented $|\log 2FoldChange| = 0.5$. (k) GO pathway 878 enrichment analysis for biological process in Ybx1-sgRNA AML12 cells, up-regulated 879 and down-regulated DEG thresholds: p < 0.05, $|\log 2$ FoldChange| > 0.5. 880

881

Figure 8 YBX1 regulates ANGPTL8 expression and liver lipid metabolism *in vivo*.
(a) Pictures of AAV infected livers. (b-d) Levels of *Angptl8* mRNA (b) and protein
(c-d) in AAV-*Ybx1*-shRNA mouse livers. (e, f) Body weights (e) and food intake (f) of

AAV-EV and AAV-Ybx1-shRNA mice. (g) Relative tissue weight, fat mass, and lean

mass of AAV-EV and AAV-Ybx1-shRNA mice under HFD for 16 weeks. (h) Glucose

tolerance test of mice under HFD for 12 weeks. (i- j) TRIG (i) and CHOL (j) levels in 887 serum and liver of AAV-EV and AAV-Ybx1-shRNA mice. (k) Oil red staining of 888 mouse livers under HFD for 16 weeks. (1) Volcano plot showing the DEGs with 889 statistical significance (thresholds: p < 0.05) and fold change (thresholds: 890 $|\log 2FoldChange| \ge 1$) in the livers of AAV-EV and AAV-Ybx1-shRNA mice. (m) GO 891 892 pathway enrichment analysis for biological process in the livers of AAV-Ybx1-shRNA mice, up-regulated and down-regulated DEG thresholds: p < 0.05, $|\log 2FoldChange| >$ 893 1. (n-p) Region plot of association between YBX1 locus (n), YBX2 locus (o) and 894 PCBP1 locus (p), and CHOL trait. 895

896